中德临床肿瘤学杂志（英文版）2009，Vol.8Issue(5)：265-268,4.DOI:10.1007/s10330-009-0043-5
ERCC-1、sruvivin表达与含顺铂方案-线化疗冶疗晚期肺腺癌患者疗效和预后关系
Relationship between the expression of ERCC-1,survivin and both efficiency and prognosis of cisplatin contained first-line chemotherapy in advanced lung adenocarcinoma
摘要
Abstract
Immunohistochemical (IHC) method was used to evaluate the expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line chemotherapy. The response rate and survival time were analyzed according to the expression of ERCC-1 and survivin. Results:Only 77 patients could be reviewed by IHC staining. The expression rates of ERCC-1 and survivin were 33.77% and 53.25 % respectively. The worse response rate and shorter TTP/PFS could be identified in ERCC-1 positive group. Patients with positive expression of survivin had worse survival time. Conclusion:Expression of ERCC-1 may be a molecular marker of cisplatincontained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma patients. Positive expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.关键词
lung adenocarcinoma/ERCC-1/survivin/cisplatinKey words
lung adenocarcinoma/ERCC-1/survivin/cisplatin分类
医药卫生引用本文复制引用
Xiaobing Chen,Suxia Luo,Ning Li,Yongping Song,Junjie Zen..ERCC-1、sruvivin表达与含顺铂方案-线化疗冶疗晚期肺腺癌患者疗效和预后关系[J].中德临床肿瘤学杂志（英文版）,2009,8(5):265-268,4.基金项目
Supported by a grant from the Science and Technology Key Project of Henan Province (No.200538). （No.200538）
